Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06402942
Other study ID # LHU20241004
Secondary ID LHÜ
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date May 8, 2025

Study information

Verified date May 2024
Source Lokman Hekim Üniversitesi
Contact Basak Çagla Arslan, Master Degree
Phone 4448548
Email ptbasakc@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research aims to improve the quality of life, occupational performance, occupational satisfaction and emotional health of young people with Duchenne muscular dystrophy compared to the classical occupational therapy program. The findings are planned to shed light on the development of new and effective strategies in the rehabilitation of adolescents with Duchenne muscular dystrophy.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 8, 2025
Est. primary completion date March 21, 2025
Accepts healthy volunteers No
Gender Male
Age group 13 Years to 18 Years
Eligibility Inclusion Criteria: - Being diagnosed with Duchenne muscular dystrophy - To be literate in Turkish - To have scored 27 points or more on the Modified Mini Mental Test - Having a computer, tablet and internet connection - Volunteering to participate in the study by their parents and reading and signing the informed consent form Exclusion Criteria: - Having a neurological disease other than Duchenne muscular dystrophy and/or another diagnosed neurological disease accompanying Duchenne muscular dystrophy - Having a cooperation problem that prevents completing the assessments for any reason - Difficulty understanding and speaking the Turkish language

Study Design


Intervention

Other:
Gamified occupational therapy programme
Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
Classic occupational therapy programme
Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks

Locations

Country Name City State
Turkey Lokman Hekim University Ankara

Sponsors (2)

Lead Sponsor Collaborator
Basak Çagla Arslan Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Demographic information form At the start of the evaluations
Primary Modified Mini Mental State Test before and after the eight-week intervention programs
Primary Vignos lower extremity functional scale This scale was developed to assess the level of ambulation in neuromuscular diseases and consists of 10 stages. In this scale, the ambulation level of the person decreases from the first stage to the tenth stage. before and after the eight-week intervention programs
Primary Brooke upper extremity functional classification scale This scale was developed to assess the functional levels of the upper extremity in neuromuscular diseases and consists of 6 stages. In this scale, progression from the first stage to the sixth stage indicates a decrease in the functionality of the upper extremity. before and after the eight-week intervention programs
Primary The Pediatric Quality of Life Inventory 3.0 Neuromuscular Module before and after the eight-week intervention programs
Primary Canadian Occupational Performance Measure before and after the eight-week intervention programs
Primary The Hospital Anxiety and Depression Scale (HADS) Of the total 14 items in the scale, odd-numbered items measure anxiety and even-numbered items measure depression. The scores to be obtained from the sub-dimensions of the scale are between 0-21. The measurement results of the sub-dimensions indicate clinical distress with a total score of 7.5 for anxiety and a total score of 5.5 for depression. For each subscale, there are recommended cut-off scores of 8-10 points for mild severity, 11-15 points for moderate severity and 16 points and above for severe severity. before and after the eight-week intervention programs
Primary The Pediatric Quality of Life Inventory Multidimensional Fatigue Scale This scale consists of 18 items and 3 subsections: general fatigue (6 items), fatigue during sleep/rest (6 items) and cognitive fatigue (6 items). Separate scores can be calculated for each subsection and the total score is obtained by summing the scores obtained from these sections. High scores indicate low fatigue. before and after the eight-week intervention programs
Primary The Numeric Rating Scale - Pain This scale uses a 10-centimeter line. The left beginning of the line represents "no pain" (0 points) and the end of the line represents "excruciating pain" (10 points). before and after the eight-week intervention programs
See also
  Status Clinical Trial Phase
Completed NCT05575648 - Dual Task in Duchenne Muscular Dystrophy N/A
Terminated NCT03907072 - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2/Phase 3
Not yet recruiting NCT06450639 - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy Phase 2
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Active, not recruiting NCT04906460 - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) Phase 1/Phase 2
Active, not recruiting NCT02500381 - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) Phase 3
Enrolling by invitation NCT05967351 - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study Phase 3
Recruiting NCT03067831 - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT01834040 - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Phase 1/Phase 2
Completed NCT02246478 - A Study of TAS-205 for Duchenne Muscular Dystrophy Phase 1
Active, not recruiting NCT01772043 - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping N/A
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Completed NCT00758225 - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) Phase 2
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting NCT03513367 - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting NCT05712447 - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT03319030 - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated NCT01753804 - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy. N/A
Completed NCT02530905 - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Phase 1